Oasis Pharmaceuticals

Oasis Pharmaceuticals is a clinical-stage pharmaceutical company developing therapies based on its proprietary Pepducin technology platform that targets Protease-Activated Receptor 2 (PAR2) to treat fibrotic and inflammatory diseases. The company's lead candidate, OA-235i, is in Phase 2 development for metabolic dysfunction-associated steatohepatitis (MASH), while OA-3, a topical agent, is in Phase 1b trials for atopic dermatitis, with additional programs in development for respiratory and ot...